- Home
- BIIB vs ATO Comparison
BIIB vs ATO Comparison
Compare BIIB & ATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ATO
- Stock Information
- Founded
- BIIB 1978
- ATO 1906
- Country
- BIIB United States
- ATO United States
- Employees
- BIIB N/A
- ATO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ATO Oil/Gas Transmission
- Sector
- BIIB Health Care
- ATO Utilities
- Exchange
- BIIB Nasdaq
- ATO Nasdaq
- Market Cap
- BIIB 24.2B
- ATO 28.3B
- IPO Year
- BIIB 1991
- ATO 1987
- Fundamental
- Price
- BIIB $182.14
- ATO $172.99
- Analyst Decision
- BIIB Buy
- ATO Hold
- Analyst Count
- BIIB 23
- ATO 9
- Target Price
- BIIB $176.48
- ATO $167.50
- AVG Volume (30 Days)
- BIIB 2.1M
- ATO 1.1M
- Earning Date
- BIIB 10-30-2025
- ATO 11-05-2025
- Dividend Yield
- BIIB N/A
- ATO 2.29%
- EPS Growth
- BIIB N/A
- ATO 9.22
- EPS
- BIIB 10.97
- ATO 7.46
- Revenue
- BIIB $10,065,900,000.00
- ATO $4,702,755,000.00
- Revenue This Year
- BIIB $2.97
- ATO $15.80
- Revenue Next Year
- BIIB N/A
- ATO $6.83
- P/E Ratio
- BIIB $16.11
- ATO $23.40
- Revenue Growth
- BIIB 4.77
- ATO 12.91
- 52 Week Low
- BIIB $110.04
- ATO $136.05
- 52 Week High
- BIIB $185.17
- ATO $180.65
- Technical
- Relative Strength Index (RSI)
- BIIB 80.42
- ATO 44.36
- Support Level
- BIIB $165.75
- ATO $173.56
- Resistance Level
- BIIB $185.17
- ATO $176.11
- Average True Range (ATR)
- BIIB 5.72
- ATO 2.51
- MACD
- BIIB 1.78
- ATO -0.52
- Stochastic Oscillator
- BIIB 90.75
- ATO 0.13
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About ATO Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3.3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.